Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Long-term Use of Bisphosphonates Lowers Risk of Colorectal Cancer

By LabMedica International staff writers
Posted on 01 Mar 2011
Bisphosphonates, calcium-regulating drugs that inhibit bone resorption and used in the treatment of hypercalcemia and osteoporosis in humans, have been found to reduce the risk of developing colorectal cancer.

In addition to being used for treatment of osteoporosis, bisphosphonates are also used to treat bone metastases caused by breast cancer, and were recently reported to be associated with a reduced risk of the disease. More...
To see if treatment with bisphosphonates would correlate with reduced risk for other types of cancer, investigators at the Technion--Israel Institute of Technology (Haifa, Israel) evaluated the use of bisphosphonates with the risk for developing colorectal cancer.

Data on the long-term use of bisphosphonates before diagnosis by 1,866 postmenopausal female participants was extracted from the Molecular Epidemiology of Colorectal Cancer (MECC) study, a population-based case-control study in northern Israel.

Results published in the February 14, 2011, online edition of the Journal of Clinical Oncology revealed that the use of bisphosphonates for more than one year before diagnosis, but not for less than one year, was associated with a significantly reduced relative risk of colorectal cancer. This association remained statistically significant after adjustment in a model for vegetable consumption, sports activity, family history of colorectal cancer, body mass index, and use of low-dose aspirin, statins, vitamin D, and postmenopausal hormones.

Overall, the use of oral bisphosphonates for more than one year was associated with a 59% relative reduction in the risk of colorectal cancer, similar to the recently reported association of this drug class with reduction in breast cancer risk.

"We formerly identified a new class of drugs associated with a reduced risk of breast cancer,” said first author Dr. Gad Rennert, professor of medicine at the Technion--Israel Institute of Technology. "And, now, by showing a similar effect on colorectal cancer risk reduction, we can assume that this class of medications has a broad effect - not necessarily limited to a specific cancer site.”

"While the disease is generally caused by bad dietary habits and lack of physical activity, it can possibly be prevented by several medications, such as aspirin and cholesterol-lowering medication of the statins group,” said Dr. Rennert. "And now, we can add bisphosphonates to the list of tools for potential prevention of colorectal cancer.”

Related Links:

Technion-Israel Institute of Technology



New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic CLIA Analyzer
Shine i6000
New
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The genomic test measures eight gene activities in a melanoma tumor and combines this data with patient factors like age and tumor thickness (Photo courtesy of 123RF)

Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients

Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.